TRICOR

This brand name is authorized in United States. It is also authorized in Croatia, Japan, South Africa.

Active ingredients

The drug TRICOR contains one active pharmaceutical ingredient (API):

1	Fenofibrate UNII U202363UOS - FENOFIBRATE
	Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
	Read more about Fenofibrate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRICOR Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AB05	Fenofibrate	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HR	Agencija za lijekove i medicinske proizvode	HR-H-399248813, HR-H-782085853
JP	医薬品医療機器総合機構	2183006F3031, 2183006F4038
US	FDA, National Drug Code	0074-3173, 0074-3189, 43353-272
ZA	Health Products Regulatory Authority	41/7.5/0848